UNSPSC 51141594: Milacemide hydrochloride

This classification denotes an anticonvulsant agent with the molecular formula C7H16N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6XK4G40F6W, chemically known as acetamide, 2-(pentylamino)-, monohydrochloride but more generally known as milacemide hydrochloride, which bears US NIH Compound Identifier 53568. Most nations, for tariff and trade purposes, schedule milacemide hydrochloride under HS 29241900 and SITC 51471. As of Q4 2014, MILACEMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Milacemide hydrochloride bears US NLM identifiers UMLS ID C2825649 and NCI Concept Code C81470. SMILES: CCCCCNCC(=O)N.CL.

UNSPSC 51141594 Milacemide hydrochloride is a Commodity code with minimal alignment between its nominal scope and recent state and local procurement activity. The three recorded opportunities under this code actually solicit naloxone and drug deactivation systems, therapeutic pharmacy initiative direct-to-manufacturer prescriptions, and generic multi-source pharmaceuticals and OTC products—none of which are milacemide hydrochloride. The code shows little relevant recent activity specific to its stated pharmaceutical compound; the tagging appears to reflect a broader categorization of pharmaceutical procurement rather than targeted sourcing of this particular drug formulation.

Issuing bodies include Seminole County, Florida (a county health department procurement); the Texas Health and Human Services Commission (a state agency); and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (a cooperative purchasing vehicle spanning multiple states and local jurisdictions including Oregon). Representative recent opportunities include Seminole County's IFB60459723LAS, an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription capabilities, posted April 3, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026. Geographic activity centers on Florida, Texas, and Minnesota with multi-state reach through the cooperative purchasing mechanism. Given the mismatch between the code's name and actual procurement substance, this code does not represent a coherent procurement signal for milacemide hydrochloride specifically.